menu

Quintiles Library

Show Filters
Presentation
Coverage and reimbursement of new treatments for orphan diseases will become increasingly restrictive in the years to come. In this webinar, our experts offer strategies on ways to meet the challenges to market access in a time of increased pushback from patients, payers and regulators.
Explore More
Presentation
With increasing pricing pressures in a therapeutic area which has seen many recent drug approvals, diabetes drug developers are seeking to enhance their clinical development and portfolio. By leveraging Continuous Glucose Monitoring (CGM), sponsors conducting trials in diabetes as well as other indications have the potential to enhance patient safety, accelerate clinical...
Explore More
Presentation
While privacy is the responsibility of all healthcare organizations, life-science companies and real-world evidence (RWE) leaders are driving and benefiting from the implementation of new global privacy standards in the health data sharing space. Leading companies are building dedicated RWE evidence platforms in specific disease areas that extend across multiple countries...
Explore More
Presentation
A presentation given at the iCAN Summit 2017 answers questions about how we can improve the care of children. Here’s what's being asked: Who is doing the research? Overview of basic industry sponsored research and the different entities involved Why we care about pediatric trials? The facts and regulations How can we help improve care for children? Pediatric...
Explore More
White Paper
Alzheimer’s Disease continues to be a common cause of death in elderly patients. To successfully address five critical challenges in this therapy area, pharma and biotech must adopt an 'act now' mentality, working together to make headway against this complex disease.
Explore More
White Paper
Increasing leverage of electronic health records (EHRs), imaging systems and social media is delivering groundbreaking patient-centric insight. However, as companies seek deeper understanding of health outcomes via patient-level data, privacy-enhancing capabilities are becoming a critical source of leadership – and key to unlocking the full value of real-world evidence...
Explore More
Infographic
QuintilesIMS takes oncology expertise to a new level. With meaningful insights based on the world’s largest curated healthcare data source and advanced analytics. You’ll discover ways to improve clinical trials. More robust evidence to support treatments. A clearer picture of the patient journey. And insights that actually lead to better commercial performance.
Read More
Presentation
As if patient identification and engagement weren’t challenging enough, add in a rare disease study, and it can feel like a daunting process. Patient populations are small and widely dispersed around the globe, and finding the proper sites to support these patients is difficult. As an emerging biopharma company, limited resources can make these challenges that much...
Explore More
Fact Sheet
Risk-based monitoring (RBM) continues to transform clinical development using data insights delivered by innovative technology, enhanced processes and new roles to optimize execution. Biopharma is adopting RBM as the standard execution model for their studies. QuintilesIMS is leading this evolution with an expanded RBM offering, Centralized Monitoring. Learn more about...
Read More
Presentation
Effective patient engagement and empowerment – patients’ involvement in their own healthcare and decision-making – is of vital importance. Why? Because it has the potential to improve treatment adherence, health outcomes and patient quality of life. Peter Rutherford will explore the importance of patient engagement and the impact on health outcomes; Chris Kelly will...
Explore More
Video
QuintilesIMS provides deep experience for superior delivery of your Phase I trial to help you drive healthcare forward. Your early clinical development is critical to the success of getting your molecule to market. Named the leader in Phase I studies for five consecutive years, QuintilesIMS provides deep experience in conducting first-in-human or healthy volunteer...
White Paper
Early clinical development (ECD) studies have become increasingly complex and expensive in recent years. One approach to address this is the use of a site network model to ensure we are utilizing the geography and site best suited for a particular study and therapeutic area. This approach allows a blending of timelines, cost, experience, and quality to ensure the best...
Explore More
Fact Sheet
Improving patient safety is our #1 priority. When you partner with QuintilesIMS, our experienced cross-functional teams will deliver comprehensive and innovative patient safety solutions across your product’s lifecycle – from clinical through post-approval.
Read More
Fact Sheet
Regenerative medicine is transitioning from the lab to the clinic and facing a shifting regulatory landscape, constrained clinical manufacturing capacity, and limited sites with stem cell clinical trial experience. Working with California Institute for Regenerative Medicine (CIRM) and its Alpha Stem Cell Clinics, the Stem Cell Center plays a role in providing guidance...
Read More
Fact Sheet
Regenerative medicine is transitioning from the lab to the clinic and facing a shifting regulatory landscape, constrained clinical manufacturing capacity, and limited sites with stem cell clinical trial experience. Working with California Institute for Regenerative Medicine (CIRM) and its Alpha Stem Cell Clinics, the Stem Cell Center plays a role in providing guidance...
Read More
Article
Specialised, field-based Medical Affairs services can enable effective, compliant therapeutic area and product understanding prior to launch to help facilitate and sustain optimal patient access to medicines. In an environment where clear, transparent and compliant communication is increasingly required, Medical Science Liaisons (MSLs) provide a credible link to external...
Explore More
Article
Life sciences companies spend an average of $300,000 to recruit each participant for a Phase III clinical trial. However, despite this investment, 80% of trials fail to meet their initial patient enrolment quotas. Challenges associated with the identification of subjects to participate in a study can cause serious bottlenecks and delay study completion, slowing...
Explore More
Article
The aim of medical care is to improve survival and quality of life for patients. Those with long-term and life-limiting conditions have particular needs due to the progressive and/or long-term nature of the underlying pathophysiology. However, it is now clear that patients who are engaged in their own health and treatment may have better outcomes. Biopharma companies...
Explore More
Fact Sheet
The market access challenge requires a successful response to multiple stakeholders from different countries – each with their own needs and requirements. Anticipating these diverse demands and developing the necessary evidence requires a nuanced understanding of the dynamic payer environments you must navigate. QuintilesIMS’s HTA Accelerator offers an integrated solution...
Read More